CTI BioPharma (CTIC) Gets a Buy Rating from Brookline Capital Markets

In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on CTI BioPharma (CTICResearch Report), with a price target of $12.00. The company’s shares closed last Thursday at $3.66.

According to TipRanks.com, Cann is a 1-star analyst with an average return of -1.3% and a 38.8% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Syros Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CTI BioPharma with a $8.44 average price target, implying a 128.7% upside from current levels. In a report issued on May 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $6.20 price target.

See the top stocks recommended by analysts >>

CTI BioPharma’s market cap is currently $358.6M and has a P/E ratio of -3.31.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More